TWI404717B - 氟化胺基三唑衍生物 - Google Patents

氟化胺基三唑衍生物 Download PDF

Info

Publication number
TWI404717B
TWI404717B TW099118594A TW99118594A TWI404717B TW I404717 B TWI404717 B TW I404717B TW 099118594 A TW099118594 A TW 099118594A TW 99118594 A TW99118594 A TW 99118594A TW I404717 B TWI404717 B TW I404717B
Authority
TW
Taiwan
Prior art keywords
ethyl
compound
methyl
triazol
difluoro
Prior art date
Application number
TW099118594A
Other languages
English (en)
Chinese (zh)
Other versions
TW201102383A (en
Inventor
Daniel Bur
Olivier Corminboeuf
Sylvaine Cren
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of TW201102383A publication Critical patent/TW201102383A/zh
Application granted granted Critical
Publication of TWI404717B publication Critical patent/TWI404717B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
TW099118594A 2009-06-09 2010-06-08 氟化胺基三唑衍生物 TWI404717B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2009052445 2009-06-09

Publications (2)

Publication Number Publication Date
TW201102383A TW201102383A (en) 2011-01-16
TWI404717B true TWI404717B (zh) 2013-08-11

Family

ID=42371383

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099118594A TWI404717B (zh) 2009-06-09 2010-06-08 氟化胺基三唑衍生物

Country Status (22)

Country Link
US (1) US8580831B2 (enExample)
EP (1) EP2440555B1 (enExample)
JP (2) JP5095035B2 (enExample)
KR (1) KR101444559B1 (enExample)
CN (1) CN102414207B (enExample)
AR (1) AR077032A1 (enExample)
AU (1) AU2010258334B2 (enExample)
BR (1) BRPI1010738A8 (enExample)
CA (1) CA2760588C (enExample)
CL (1) CL2011003097A1 (enExample)
ES (1) ES2587139T3 (enExample)
IL (1) IL216792A (enExample)
MA (1) MA33420B1 (enExample)
MX (1) MX342440B (enExample)
MY (1) MY161243A (enExample)
NZ (1) NZ597453A (enExample)
PL (1) PL2440555T3 (enExample)
RU (1) RU2544862C2 (enExample)
SG (1) SG175363A1 (enExample)
TW (1) TWI404717B (enExample)
WO (1) WO2010143116A1 (enExample)
ZA (1) ZA201200127B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
BRPI0821115A8 (pt) 2007-12-18 2017-12-26 Actelion Pharmaceuticals Ltd Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
JP5510945B2 (ja) 2009-05-18 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド Alx受容体及び/又はfprl2アゴニストとしての架橋スピロ[2.4]ヘプタン誘導体
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
WO2012066488A2 (en) 2010-11-17 2012-05-24 Actelion Pharmaceuticals Ltd Bridged spiro[2.4]heptane ester derivatives
EP2648724B1 (en) 2010-12-07 2016-09-21 Actelion Pharmaceuticals Ltd. Hydroxylated aminotriazole derivatives as alx receptor agonists
PL2649068T3 (pl) 2010-12-07 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX
EP2850058B1 (en) 2012-05-16 2016-07-13 Actelion Pharmaceuticals Ltd. 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
US10370451B2 (en) 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
BR112016001106A8 (pt) 2013-07-18 2017-12-26 Actelion Pharmaceuticals Ltd Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
BR112023024873A2 (pt) 2021-06-01 2024-02-15 Azcuris Co Ltd Composto derivado de oxazol, composição farmacêutica compreendendo o mesmo, uso do composto derivado de oxazol e composição de alimento para melhorar os sintomas de doenças alérgicas

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
KR20030030029A (ko) 2000-09-22 2003-04-16 니혼노야쿠가부시키가이샤 N-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
JP2005536187A (ja) 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
PT1791830E (pt) * 2004-09-17 2011-04-04 Vertex Pharma Compostos de diaminotriazole úteis como inibidores de proteína-quinase
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
CA2626897A1 (en) 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
HUE025137T2 (en) 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
BRPI0821115A8 (pt) * 2007-12-18 2017-12-26 Actelion Pharmaceuticals Ltd Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
JP5510945B2 (ja) 2009-05-18 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド Alx受容体及び/又はfprl2アゴニストとしての架橋スピロ[2.4]ヘプタン誘導体
CA2760887A1 (en) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hungate et al, Bioorganic & Medicinal Chemistry Letters, 2006, 16, p3713-3718 *

Also Published As

Publication number Publication date
ZA201200127B (en) 2014-06-25
JP5775496B2 (ja) 2015-09-09
BRPI1010738A8 (pt) 2017-12-26
MY161243A (en) 2017-04-14
US8580831B2 (en) 2013-11-12
EP2440555A1 (en) 2012-04-18
TW201102383A (en) 2011-01-16
MX2011012739A (es) 2011-12-16
PL2440555T3 (pl) 2016-11-30
CN102414207A (zh) 2012-04-11
IL216792A0 (en) 2012-02-29
MX342440B (es) 2016-09-29
CA2760588C (en) 2017-08-08
AU2010258334B2 (en) 2015-02-26
ES2587139T3 (es) 2016-10-20
NZ597453A (en) 2013-03-28
KR20120089380A (ko) 2012-08-09
EP2440555B1 (en) 2016-05-18
KR101444559B1 (ko) 2014-09-26
CL2011003097A1 (es) 2012-07-06
IL216792A (en) 2014-05-28
WO2010143116A1 (en) 2010-12-16
JP2012529491A (ja) 2012-11-22
CN102414207B (zh) 2015-09-30
AU2010258334A1 (en) 2012-02-02
CA2760588A1 (en) 2010-12-16
JP2012255002A (ja) 2012-12-27
BRPI1010738A2 (pt) 2016-03-15
MA33420B1 (fr) 2012-07-03
US20120101138A1 (en) 2012-04-26
JP5095035B2 (ja) 2012-12-12
AR077032A1 (es) 2011-07-27
RU2544862C2 (ru) 2015-03-20
SG175363A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CN102414207B (zh) 氟化氨基三唑衍生物
EP2649068B1 (en) Oxazolyl-methylether derivatives as alx receptor agonists
KR101847672B1 (ko) Alx 수용체 작용제로서의 히드록실화 아미노트리아졸 유도체
US8536209B2 (en) Aminotriazole derivatives as ALX agonists

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees